Patents by Inventor Anastasia Khvorova

Anastasia Khvorova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • siRNA targeting LDHA
    Patent number: 10920226
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for LDHA.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 16, 2021
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • RNA interference in dermal and fibrotic indications
    Patent number: 10913948
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • FULLY STABILIZED ASYMMETRIC SIRNA
    Publication number: 20210024926
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: July 13, 2020
    Publication date: January 28, 2021
    Inventors: Anastasia Khvorova, Neil Aronin, Matthew Hassler, Julia Alterman
  • Reduced size self-delivering RNAI compounds
    Patent number: 10876119
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 29, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
    Publication number: 20200385740
    Abstract: This disclosure relates to novel modified oligonucleotides. Novel modified siRNA are also provided.
    Type: Application
    Filed: March 26, 2020
    Publication date: December 10, 2020
    Inventors: Anastasia Khvorova, Loïc Maurice René Jean Roux, Ken Yamada
  • OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
    Publication number: 20200385737
    Abstract: This disclosure relates to novel C9ORF72 targeting sequences. Novel oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: December 10, 2020
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, James W. Gilbert
  • Two-tailed self-delivering siRNA
    Patent number: 10844377
    Abstract: Provided are compositions and methods comprising two-tailed siRNAs (tt-siRNAs) that exhibit unprecedented cellular uptake and silencing. Also provided are methods of treating neurological and other diseases with the two-tailed siRNAs of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 24, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Julia Alterman, Matthew Hassler
  • OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
    Publication number: 20200362341
    Abstract: This disclosure relates to novel ApoE targeting sequences. Novel oligonucleotides for the treatment of neurodegenerative and amyloid-related diseases are also provided.
    Type: Application
    Filed: March 13, 2020
    Publication date: November 19, 2020
    Inventors: Anastasia Khvorova, Chantal Ferguson, Evgeny Rogaev
  • BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY
    Publication number: 20200339983
    Abstract: Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.
    Type: Application
    Filed: March 9, 2020
    Publication date: October 29, 2020
    Inventors: Anastasia Khvorova, Mehran Nikan, Matthew Hassler, Maire Osborn, Reka Haraszti, Andrew Coles, Anton Turanov, Neil Aronin
  • RNA interference in skin indications
    Patent number: 10815485
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: October 27, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Branched oligonucleotides
    Patent number: 10799591
    Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: October 13, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
  • RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITY
    Publication number: 20200308578
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Application
    Filed: November 11, 2019
    Publication date: October 1, 2020
    Applicant: PHIO PHARMACEUTICALS CORP.
    Inventors: TOD M. WOOLF, JOANNE KAMENS, WILLIAM SALOMON, ANASTASIA KHVOROVA
  • OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA
    Publication number: 20200308584
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 1, 2020
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • Oligonucleotide compounds for targeting huntingtin mRNA
    Patent number: 10774327
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • Reduced size self-delivering RNAI compounds
    Patent number: 10774330
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 15, 2020
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES
    Publication number: 20200283801
    Abstract: In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobically modified oligonucleotide cargo, and uses thereof, are also provided.
    Type: Application
    Filed: December 13, 2019
    Publication date: September 10, 2020
    Inventors: Anastasia Khvorova, Neil Aronin, Marie Cecile Didiot, Reka Haraszti
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 10765695
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 8, 2020
    Assignee: Thermo Fisher Scientific Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS
    Publication number: 20200270605
    Abstract: Therapeutic oligonucleotides comprising pharmacokinetic (PK)-modifying anchors are provided. Methods for treating diseases or disorders comprising administering to a subject a therapeutic oligonucleotide comprising one or more PK-modifying anchors are provided.
    Type: Application
    Filed: January 17, 2020
    Publication date: August 27, 2020
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, Matthew Hassler
  • Methods and Compositions for Selecting siRNA of Improved Functionality
    Publication number: 20200270607
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 27, 2020
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 10696968
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for HAO1.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: June 30, 2020
    Assignee: THERMO FISHER SCIENTIFIC INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe